Phone: (707) 546-5553
Email Us
1140 Sonoma Avenue 1-A
Santa Rosa, CA 95405

prostate cancer cure

Dr. Michael Lazar Offers Free HIFU Presentation Online

Dr. Michael Lazar of California HIFU recently gave a presentation in Santa Rosa discussing the benefits of high-intensity focused ultrasound for prostate cancer and now offers the presentation online.

A public presentation recently held in Santa Rosa for a group gathered to learn more about high-intensity focused ultrasound (HIFU) provided an overview of how this exciting new prostate cancer treatment works, and included comparisons to other treatment options, as well as HIFU patient outcomes. The event also offered people a chance to meet Dr. Lazar who is a four-time board certified urologist and prostate cancer specialist providing HIFU to patients in California. It also gave attendees a chance to learn more prostate cancer and to ask important questions.

During the presentation, Dr. Lazar discussed how HIFU offers hope for prostate cancer patients by targeting cancer cells through a focused precision technology with minimal to no side effects. The procedure is accomplished in a one to four-hour session and patients return to their normal routines fairly quickly. “Our recent presentation was so well received, we wanted to be able to offer it to a wider audience,” explained Dr. Lazar. “By providing this information to patients online we hope to be able to educate men who currently have prostate cancer about HIFU as a treatment option, and to perhaps provide some important answers to unasked questions.”

About HIFU

Although relatively new to the U.S. Sonablate® technology has been used around the world on more than 15,000 patients in over 30 countries for more than 15 years. Approximately 4,000 U.S. men have received HIFU treatment outside the U.S. prior to FDA approval.

“I started treating with HIFU in 2007 and since receiving FDA approval in 2015 began offering the treatment in San Francisco,” Dr. Lazar said.  Prior to FDA approval Dr. Lazar explained that he performed outpatient procedures at a U.S. Joint Commission approved bilingual hospital in Mexico – helping to bring this innovative prostate cancer treatment to hundreds of men diagnosed with the disease. During that time, Dr. Lazar also served as a HIFU instructor for other physicians and is now actively training doctors in HIFU for prostate cancer in San Francisco.

Serving as Medical Director for HIFU Prostate Services (HPS) Dr. Lazar founded California HIFU to provide HIFU services in the San Francisco area, the first such facility on the west coast. Since that time HIFU using Sonablate® technology has become available in more than 40 locations across the nation.

For patients with prostate cancer, HIFU treatment is most effective in the early stages, where it is localized to the prostate. Performed on an out-patient basis, the procedure is able to preserve healthy tissue and nerves, so urine flow and erectile function is maintained in a high percent of cases. “This is an extremely well tolerated procedure,” said Dr. Lazar. “Patients return to normal activity very quickly. There is no blood loss and very little pain when compared to other treatments for prostate cancer.”

Dr. Lazar explains how all prostate cancer treatments can have side effects. But with HIFU the side effects are lower than with any of the other treatments for prostate cancer. “Unique to HIFU, if you have an HIFU treatment and still require additional treatment, patients can opt to have a second HIFU treatment, or any other treatment they decide to pursue,” he says.

The presentation is free and available online on the California HIFU YouTube Channel accessible by following this link: HIFU YouTube Channel.

About Dr. Lazar

Dr. Lazar is part of Northern California Medical Associates and operates California HIFU in Santa Rosa. He is the medical director of HIFU Prostate Services, LLC, a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). Dr. Lazar is also a clinical partner with HPS with the HIFU San Francisco Surgery Center of Excellence, a state-of-the-art facility that is convenient to hotels and the airport.  For more information about Dr. Lazar, HIFU treatment for prostate cancer visit the HIFU website or to make an appointment call: (707) 546-5553.

 

 

By | March 6th, 2017|HIFU, News|0 Comments

Researchers target cholesterol to stop prostate cancer

Advanced prostate cancer and high blood cholesterol have long been known to be connected, but it has been a chicken-or-egg problem.

Now a team led by researchers at the Duke Cancer Institute have identified a cellular process that cancer cells hijack to hoard cholesterol and fuel their growth. Identifying this process could inform the development of better ways to control cholesterol accumulation in tumors, potentially leading to improved survival for prostate cancer patients.

The findings are published online this month in the journal Cancer Research.

“Prostate cancer cells, as well as some other solid tumors, have been shown to contain higher cholesterol levels than normal cells,” said senior author Donald McDonnell, Ph.D., chairman of the Department of Pharmacology and Cancer Biology at Duke. “All cells need cholesterol to grow, and too much of it can stimulate uncontrolled growth.

“Prostate cancer cells somehow bypass the cellular control switch that regulates the levels of cholesterol allowing them to accumulate this fat,” McDonnell said. “This process has not been well understood. In this study, we show how prostate cancer cells accomplish this.”

McDonnell and colleagues began by identifying genes involved in cholesterol regulation in prostate tumors. They homed in on a specific gene, CYP27A1, which is a key component of the machinery that governs the level of cholesterol within cells.

In patients with prostate cancer, the expression of the CYP27A1 gene in tumors is significantly lower, and this is especially true for men with aggressive cancers compared to the tumors in men with more benign disease. Downregulation of this gene basically shuts off the sensor that cells use to gauge when they have taken up enough cholesterol. This in turn allows accumulation of this fat in tumor cells. Access to more cholesterol gives prostate cancer cells a selective growth advantage.

“It remains to be determined how this regulatory activity can be restored and/or whether it’s possible to mitigate the effects of the increased cholesterol uptake that result from the loss of CYP27A1 expression,” McDonnell said.

He said statin use alone might help, but perhaps not enough, since tumors could simply rev up the regulation of the cholesterol manufacturing process in tumors to compensate.

McDonnell said is lab is continuing the research, including finding ways to induce cells to eject cholesterol, reverse the inhibition of CYP27A1 activity, or introduce compounds that interfere with cholesterol-production in the tumor.


Story Source:

Materials provided by Duke University Medical Center. Note: Content may be edited for style and length.


Journal Reference:

  1. Mahmoud A Alfaqih, Erik R Nelson, Wen Liu, Rachid Safi, Jeff S Jasper, Everardo Macias, Joseph Geradts, Laura G Dubois, Will Thompson, Michael R Freeman, Ching-yi Chang, Jen-Tsan Chi, Donald P McDonnell, Stephen J. Freedland. CYP27A1 loss dysregulates cholesterol homeostasis in prostate cancer. Cancer Research, 2017; canres.2738.2016 DOI: 10.1158/0008-5472.CAN-16-2738

Duke University Medical Center. “Prostate cancer cells grow with malfunction of cholesterol control in cells: Shutting down this source at the root cause could improve cancer survival.” ScienceDaily. ScienceDaily, 21 February 2017. www.sciencedaily.com/releases/2017/02/170221130703.htm.
By | March 1st, 2017|Dr. Michael Lazar, News, Prostate Cancer|0 Comments